Clinical trials: CART Cells
Solid Tumor
A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid Tumors
This is a single-arm, investigator-initiated exploratory study.The study is designed to evaluate the safety and the tolerability of HER2-E-CART cells for the treatment of patients with HER2-positive, refractory advanced solid…
- Trial name
- NCT05745454
- Testing
- HER2-E-CART cells
- Volunteers
- 12 people
- Sponsor
- su haichuan
Hematological Malignancies
National Longitudinal Cohort of Hematological Diseases (NICHE) - CART
This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies.
- Trial name
- NCT06607289
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Relapsed or Refractory Neuroblastoma
A Phase I Trial of Anti-GD2 T-cells (1RG-CART)
The purpose of this first in human study is to determine the safety and feasibility of 1RG-CART therapy in patients with relapsed or refractory neuroblastoma.
- Trial name
- NCT02761915
- Testing
- Leukapheresis, Cyclophosphamide, Fludarabine
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Cancer Research UK
Malignant Mesothelioma, Pancreatic Cancer
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Malignant Mesothelioma, Pancreatic Cancer, Ovarian Tumor, Triple Negative Breast Cancer
- Trial name
- NCT02580747
- Testing
- anti-meso-CAR vector transduced T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Malignant Melanoma, Breast Cancer
Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
This is a pilot study to evaluate feasibility, safety, and preliminary evidence of efficacy for intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and…
- Trial name
- NCT03060356
- Testing
- T cells modified with RNA anti -cMET CAR
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Pennsylvania
Renal Cell Carcinoma
Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells
This is an investigator-initiated trial to evaluate the role of anti-CD70-CAR T cells in locally advanced or recurrent/metastatic renal cell carcinoma that is inoperable.
- Trial name
- NCT06586658
- Testing
- anti-CD70-CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Changzheng Hospital
Systemic Lupus Erythematosus (SLE)
Descartes-08 for Patients With Systemic Lupus Erythematosus
This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).
- Trial name
- SLE-001 (NCT06038474)
- Testing
- Descartes-08
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Cartesian Therapeutics
Glioblastoma
CART-EGFRvIII + Pembrolizumab in GBM
This is an open-label, phase 1 study to assess the safety and tolerability of EGFRvIII T cells in combination with pembrolizumab (PD-1 Inhibitor) in patients with newly diagnosed, EGFRvIII+, MGMT-unmethylated glioblastoma.
- Trial name
- NCT03726515
- Testing
- CART-EGFRvIII T cells, Pembrolizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Pennsylvania
Refractory Lupus Nephritis, Systemic Sclerosis
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), primary Sjogren syndrome combined with pulmonary artery hypertension…
- Conditions
- Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension, Other Autoimmune Diseases (AID)
- Trial name
- NCT06947460
- Testing
- CD19-BCMA CAR-T cells infusion
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Beijing GoBroad Hospital
Ovarian Cancer
Genetically Modified T Cells Against Ovarian Cancer
The primary objectives are to evaluate the safety and efficacy of infusion of autologous ovarian cancer immunogene-modified T cells (OC-IgT cells).
- Trial name
- NCT03184753
- Testing
- OC-IgT cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
B-cell Leukemia
CAR-T Immunotherapy Targeting CD19- ALL
This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients…
- Trial name
- NCT04016129
- Testing
- 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
CLL/SLL, NHL
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
- Conditions
- CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT05665062
- Testing
- SYNCAR-001, STK-009, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Synthekine
Non Hodgkin Lymphoma (NHL), Leukaemia
Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.
Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101
- Trial name
- SAPPHIRE (NCT07518329)
- Testing
- ALA-101
- Where
- 5 sites in Australia
- Volunteers
- 46 people
- Sponsor
- Arovella Therapeutics Ltd
Recurrent Glioblastoma
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
This is an open-label, phase 1b study to evaluate different approaches for CART-EGFR-IL13Ra2 dosing and further characterize the safety, feasibility, preliminary efficacy, and pharmacokinetics of CART-EGFR-IL13Ra2 cells in…
- Trial name
- NCT07209241
- Testing
- CART-EGFR-IL13Ra2 T cells
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Pennsylvania
Neoplasm, Stomach, Metastases, Neoplasm
Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)
To investigate the safety and efficacy of intraperitoneal infusion of EpCAM CAR-T cell in advanced gastric cancer with peritoneal metastasis by a prospective nonrandomized controlled trial.
- Conditions
- Neoplasm, Stomach, Metastases, Neoplasm, Neoplasm Seeding
- Trial name
- NCT03563326
- Testing
- CAR-T cells targeting EpCAM, Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jian-Kun Hu
Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma
ths study consist in testing a CAR T therapy (ARI0003 cells (antiCD19 and antiBCMA) in patients suffering relapsed NHL (that means that symptoms of NHL reappeared ) or refractory (that means that they did not respond to other…
- Trial name
- CARTD-BG-1 (NCT06097455)
- Testing
- ARI0003
- Where
- 7 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Muscular Diseases, Neuromuscular Manifestations
Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
The goal of this clinical study is to learn more about the study drug Anitocabtagene autoleucel (anito-cel), and its safety, tolerability, dosing, and preliminary effectiveness in participants with generalized myasthenia gravis…
- Conditions
- Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases
- Trial name
- NCT06626919
- Testing
- anito-cel, Cyclophosphamide, Fludarabine
- Where
- 14 sites in United States
- Volunteers
- 30 people
- Sponsor
- Kite, A Gilead Company
B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have…
- Conditions
- B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent, High Grade B-Cell Lymphoma-Recurrent
- Trial name
- NCT06209619
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Nathan Denlinger
Sarcoma, Osteoid Sarcoma
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
The aim of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have sarcoma that is relapsed or late staged.
- Conditions
- Sarcoma, Osteoid Sarcoma, Ewing Sarcoma
- Trial name
- NCT03356782
- Testing
- Sarcoma-specific CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Multiple Myeloma, Monocytes
Quantitative and Qualitative Monocytes Analysis and Their Impact on CART Cells Reponse in Multiple Myeloma
Tumoral micro-environment in malignant haematological diseases, notably in multiple myeloma, is active on plasma cells survival and proliferation.
- Conditions
- Multiple Myeloma, Monocytes, CART Cells
- Trial name
- MONOMM (NCT07180992)
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens